13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
12 檔
258.4%
During the Q1 2025 filing period, Caxton CORP (CIK: 0001388551) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.9M across 12 reported positions.
In Q1 2025, Caxton CORP adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 60 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | Stock-Other | 75.28% | — | — | |
| 2 | GLD | Spdr Gold Shares | ETF-Commodities | 7.36% | -81.50% | EXIT | |
| 3 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 4.90% | +11.69% | -58.78% | |
| 4 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.92% | — | — | |
| 5 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.81% | — | — | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.63% | — | — | |
| 7 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.22% | +2.27% | — | |
| 8 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.87% | +1.91% | — | |
| 9 | CRDF | Cardiff Oncology Inc | Stock-Other | 0.82% | — | — | |
| 10 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.71% | +1.93% | — | |
| 11 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.26% | — | — | |
| 12 | CNTX | Context Therapeutics Inc | Stock-Other | 0.22% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +71.1% | — | Add |
| 2 | GLD | Spdr Gold Shares | +2.7% | +11.04% | Trim |
| 3 | CRDF | Cardiff Oncology Inc | -9.9% | — | Trim |
| 4 | ✓ | Strongbridge Biopharma PLC | — | EXIT | Sold out |
| 5 | ✓ | Molecular Templates Inc | — | EXIT | Sold out |
| 6 | SCYXEUR | Scynexis Inc | — | EXIT | Sold out |
| 7 | SVRA | Savara Inc | — | EXIT | Sold out |
| 8 | ✓ | Kala Bio Inc Com New | — | EXIT | Sold out |
| 9 | ✓ | Sierra Oncology Inc Com | — | EXIT | Sold out |
| 10 | CTIC1USD | Cti Biopharma CORP | — | EXIT | Sold out |
| 11 | ADXNUSD | Addex Therapeutics LTD | — | EXIT | Sold out |
| 12 | ✓ | Lux Health Tech Acquisition | — | EXIT | Sold out |
| 13 | ARES | Ares Management Corporation | — | EXIT | Sold out |
| 14 | OPHTEUR | Iveric Bio Inc | — | EXIT | Sold out |
| 15 | CLDNEUR | Eiger Biopharmaceuticals Inc | — | EXIT | Sold out |
| 16 | GOOG | Alphabet Inc-cl C | — | EXIT | Sold out |
| 17 | INTU | Intuit Inc | — | EXIT | Sold out |
| 18 | PYPL | Paypal Holdings Inc | — | EXIT | Sold out |
| 19 | META | Meta Platforms Inc-class A | — | EXIT | Sold out |
| 20 | CVNA | Carvana Co | — | EXIT | Sold out |
| 21 | CDLXEUR | Cardlytics Inc | — | EXIT | Sold out |
| 22 | MCO | Moody's CORP | — | EXIT | Sold out |
| 23 | SPGI | S&p Global Inc | — | EXIT | Sold out |
| 24 | MSFT | Microsoft CORP | — | EXIT | Sold out |
| 25 | V | Visa Inc-class A Shares | — | EXIT | Sold out |
| 26 | TDG | Transdigm Group Inc | — | EXIT | Sold out |
| 27 | MA | Mastercard Inc - A | — | EXIT | Sold out |
| 28 | AMT | American Tower CORP | — | EXIT | Sold out |
| 29 | DIS | Walt Disney Co/the | — | EXIT | Sold out |
| 30 | CHTR | Charter Communications Inc-a | — | EXIT | Sold out |
| 31 | WHR | Whirlpool CORP | — | EXIT | Sold out |
| 32 | MDLZ | Mondelez International Inc-a | — | EXIT | Sold out |
| 33 | FICO | Fair Isaac CORP | — | EXIT | Sold out |
| 34 | CRM | Salesforce Inc | — | EXIT | Sold out |
| 35 | NFLX | Netflix Inc | — | EXIT | Sold out |
| 36 | ✓ | Bridgetown Holdings LTD | — | EXIT | Sold out |
| 37 | ✓ | Frazier Lifesciences Acqu Co | — | EXIT | Sold out |
| 38 | ✓ | Science Strategic Acq Alpha | — | EXIT | Sold out |
| 39 | ✓ | Humanco Acquisition CORP | — | EXIT | Sold out |
| 40 | ✓ | Elevation Oncology Inc | — | EXIT | Sold out |
| 41 | ✓ | Ajax I | — | EXIT | Sold out |
| 42 | ✓ | Gigcapital4 Inc | — | EXIT | Sold out |
| 43 | ✓ | Oncosec Med Inc | — | EXIT | Sold out |
| 44 | ✓ | Switchback Ii Corporation | — | EXIT | Sold out |
| 45 | ✓ | Boa Acquisition CORP | — | EXIT | Sold out |
| 46 | ✓ | Svf Investment CORP | — | EXIT | Sold out |
| 47 | BRK-B | Berkshire Hathaway Inc-cl B | — | NEW | New buy |
| 48 | ✓ | Isos Acquisition Corporation | — | EXIT | Sold out |
| 49 | ✓ | Primavera Capital Acquist Co | — | EXIT | Sold out |
| 50 | ✓ | Scion Tech Growth I | — | EXIT | Sold out |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 12 disclosed positions in Q1 2025.
During Q1 2025, Caxton CORP's top holdings by market value included RZLT (75.3%)、GLD (7.4%)、BRK-B (4.9%). The largest single position, RZLT, represented 75.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RZLT, GLD, BRK-B) accounted for 258.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
BRK-B
市值: $248.8K
Top Position Liquidated / Trimmed
STRONGBRIDGE BIOPHARMA PLC
前期市值: $24.0M
In Q1 2025, Caxton CORP made 72 total portfolio adjustments, initiating 9 new buys, adding to 1 positions, trimming 2 holdings, and fully liquidating 60 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.